Company Enlivex Therapeutics Ltd.

Equities

ENLV

IL0011319527

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-01 EDT			5-day change	1st Jan Change
1.61 ^USD	-3.59%		+7.33%	-40.37%

04-22	Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial	MT
04-16	Enlivex Therapeutics Receives Approval to Expand Trial of Allocetra to Treat Knee Osteoarthritis Into Denmark	MT

Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

Managers	Title	Age	Since
Oren Hershkovitz CEO	Chief Executive Officer	47	19-11-15
Dror Mevorach FOU	Founder	68	08-12-31
Shachar Shlosberger DFI	Director of Finance/CFO	47	15-12-31
Veronique Amor-Baroukh COO	Chief Operating Officer	-	-
Sigal Arad HRO	Human Resources Officer	-	-
Iris Tavor LAW	General Counsel	-	-
Einat Galamidi PRN	Corporate Officer/Principal	-	22-02-21
Oren Elmaliah AUD	Comptroller/Controller/Auditor	40	17-01-31

Members of the board	Title	Age	Since
Shai Novik CHM	Chairman	58	19-03-25
Avri Havron BRD	Director/Board Member	76	13-12-31
Brian Schwartz BRD	Director/Board Member	52	20-11-30
Roger Pomerantz BRD	Director/Board Member	67	22-05-22
Gili Hart BRD	Director/Board Member	49	13-12-31
Andrew Singer BRD	Director/Board Member	53	23-04-16

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	18,598,555	14,984,878 ( 80.57 %)	0	80.57 %

Name	Equities	%	Valuation
Kip Global Pharma Ecosystem Private Equity Fund 7.628 %	1,417,950	7.628 %	5 M $
Hadasit Bio-Holdings Ltd. /Private Equity/ 5.412 %	1,006,007	5.412 %	4 M $
Shai Novik 4.055 %	753,764	4.055 %	3 M $
Dror Mevorach 1.262 %	234,657	1.262 %	889 350 $
Avri Havron 0.9568 %	177,852	0.9568 %	674 059 $
Renaissance Technologies LLC 0.3340 %	62,089	0.3340 %	235 317 $
KSM Mutual Funds Ltd. 0.2516 %	46,766	0.2516 %	177 243 $
Morgan Stanley Capital Services LLC 0.2392 %	44,460	0.2392 %	168 503 $
IBI Mutual Funds Management (1978) Ltd. 0.2246 %	41,750	0.2246 %	158 233 $
Migdal Mutual Funds Ltd. 0.1555 %	28,899	0.1555 %	109 527 $

Enlivex Therapeutics Ltd.

14 Einstein Street

7403618, Ness Ziona

http://www.enlivex.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.61 USD

Average target price

7 USD

Spread / Average Target

+334.78%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ENLIVEX THERAPEUTICS LTD.	-40.37%	31.42M
VERTEX PHARMACEUTICALS INCORPORATED	-1.17%	102B
REGENERON PHARMACEUTICALS, INC.	+2.87%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-14.77%	21.4B
GENMAB A/S	-8.79%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-13.21%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+8.55%	13.83B
SAREPTA THERAPEUTICS, INC.	+35.75%	11.97B

Bio Therapeutic Drugs